Metex Pen (Methotrexate)

Methotrexate works by inhibiting dihydrofolate reductase, which reduces the synthesis of nucleotides needed for DNA replication. This antiproliferative effect limits the growth of rapidly dividing immune cells. It also increases extracellular adenosine and alters cytokine production, providing anti‑inflammatory and immunosuppressive benefits in autoimmune diseases.

The dose of methotrexate is individualized and set by the prescribing healthcare professional based on the specific indication, disease severity, patient weight, renal function, and other clinical factors. Dosage regimens can vary widely, and adjustments are made according to therapeutic response and laboratory monitoring.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and embryotoxicity. It is also not recommended while breastfeeding, as it may be excreted in breast milk and pose a risk to the infant. Effective contraception is required for women of child‑bearing potential.

To order Metex Pen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternatives to methotrexate include biologic agents such as TNF‑α inhibitors. While biologics target specific cytokines and often have rapid onset, methotrexate is a small‑molecule immunosuppressant that is less costly and administered via a simple subcutaneous pen. Choice of therapy depends on disease severity, patient preference, safety profile, and cost considerations.

Metex Pen must be stored in a refrigerated environment between 2 °C and 8 °C. Keep the device in its original packaging, protect it from direct light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours before use.

Metex Pen is a pre‑filled, single‑use device designed for subcutaneous injection. The patient or healthcare professional selects the prescribed dose, cleans the injection site, and presses the activation button to deliver the medication into the fatty tissue of the abdomen or thigh. Proper technique and disposal of the used pen are essential.

The most serious adverse effects include bone marrow suppression (which can lead to anemia, leukopenia, or thrombocytopenia), severe liver toxicity (potential hepatitis, fibrosis, or cirrhosis), and pulmonary toxicity such as interstitial pneumonitis. Regular laboratory monitoring of blood counts, liver enzymes, and respiratory assessment is recommended to detect these risks early.

Metex Pen should not be used by individuals who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in patients with severe renal impairment, active liver disease, or known hypersensitivity to methotrexate or any component of the formulation. Caution is advised in patients with pre‑existing blood disorders.